Quick Answer
TScan Therapeutics, Inc. reported Total Assets of $228.79 million for fiscal year 2025.
TScan Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $228.79M | -38.4% |
| 2024 | $371.12M | +36.4% |
| 2023 | $272.15M | +36.7% |
| 2022 | $199.09M | +5.8% |
| 2021 | $188.11M | +278.2% |
| 2020 | $49.74M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $262.23M | -24.7% | -12.2% |
| June 30, 2025 | $298.56M | -20.4% | -10.3% |
| March 31, 2025 | $332.71M | +38.1% | -10.3% |
| December 31, 2024 | $371.12M | +36.4% | +6.6% |
| September 30, 2024 | $348.03M | +19.4% | -7.2% |
| June 30, 2024 | $374.87M | +18.3% | +55.7% |
| March 31, 2024 | $240.83M | +38.7% | -11.5% |
| December 31, 2023 | $272.15M | +36.7% | -6.6% |
- TScan Therapeutics, Inc. showed a decrease of -38.4% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, TScan Therapeutics, Inc.’s total assets has grown by 360.0% (from $49.74 million to $228.79 million).
- The most recent figure is from TScan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: